UFP INDUSTRIES INC

For the period ended Dec 27, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

UFPI$82.66+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Equity


(in thousands of United States dollars, · · Controlling Interest Shareholders’ Equity · · ·
except share and per share data) · · · · · Additional · · · · · Accumulated Other · · · · · · · · ·
· · Common · · Paid-In · · Retained · · Comprehensive · · Noncontrolling · · · · · Temporary
· · Stock · · Capital · · Earnings · · Earnings · · Interest (NCI) · · Total · · Equity
Balance on December 31, 2022	$61,618	$294,029	$2,217,410	$(9,075)	$32,841	$2,596,823	$6,880
Net earnings (loss)			514,312		663	514,975	(518)
Foreign currency translation adjustment				9,762	4,267	14,029	388
Unrealized gain on investments and other				419		419
Other		(817)			930	113	43
Distributions to NCI					(7,355)	(7,355)
Purchase of remaining NCI of subsidiary		(1,210)			(917)	(2,127)
NCI related to business combinations						—	13,237
Cash dividends - $1.10 per share			(68,238)			(68,238)
Issuance of 32,944 shares under ESPP	33	2,717				2,750
Issuance of 820,591 shares under stock grant programs	821	14,485	22			15,328
Issuance of 124,145 shares under deferred compensation plan	124	(124)				—
Repurchase of 974,869 shares	(975)		(81,174)			(82,149)
Expense associated with share-based compensation arrangements		34,727				34,727
Accrued expense under deferred compensation plans		10,895				10,895
Balance on December 30, 2023	$61,621	$354,702	$2,582,332	$1,106	$30,429	$3,030,190	$20,030
Net earnings (loss)			414,560		5,413	419,973	(1,240)
Foreign currency translation adjustment				(16,428)	(3,441)	(19,869)	(122)
Unrealized gain on investments and other				11		11
Other		(242)				(242)
Distributions to NCI					(11,848)	(11,848)
Purchase of remaining NCI of subsidiary		8,400				8,400	(13,302)
Cash dividends - $1.32 per share			(80,782)			(80,782)
Issuance of 27,898 shares under ESPP	28	2,784				2,812
Issuance of 380,548 shares under stock grant programs	380	5,923	77			6,380
Issuance of 104,124 shares under deferred compensation plan	104	(104)				—
Repurchase of 1,409,266 shares	(1,409)	(17,686)	(140,907)			(160,002)
Expense associated with share-based compensation arrangements		37,938				37,938
Accrued expense under deferred compensation plans		11,664				11,664
Balance on December 28, 2024	$60,724	$403,379	$2,775,280	$(15,311)	$20,553	$3,244,625	$5,366
Net earnings (loss)			294,792		1,617	296,409	(417)
Foreign currency translation adjustment				15,653	2,720	18,373	(247)
Unrealized gain on investments and other				1,222		1,222
Other		(3,663)				(3,663)	310
Distributions to NCI					(3,005)	(3,005)
Purchase of remaining NCI of subsidiary						—	(549)
Cash dividends - $1.40 per share			(82,350)			(82,350)
Issuance of 29,749 shares under ESPP	30	2,441				2,471
Issuance of 222,935 shares under stock grant programs	223	3,156	270			3,649
Issuance of 113,743 shares under deferred compensation plan	114	(114)				—
Repurchase of 4,498,835 shares	(4,499)	(9,503)	(428,617)			(442,619)
Expense associated with share-based compensation arrangements		37,583				37,583
Accrued expense under deferred compensation plans		11,549				11,549
Balance on December 27, 2025	$56,592	$444,828	$2,559,375	$1,564	$21,885	$3,084,244	$4,463

See notes to consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.